Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab Combinations in Multiple Myeloma
NCT04722146Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2021
- Primary completion
- Oct 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, open-label trial of teclistamab in multiple myeloma (MM) (6 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Incidence of Adverse Events, Adverse Events by Severity and 2 more. Started Mar 2021; status: active, not recruiting.
02
Drugs
teclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04722146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04722146.